BiotechTube
Home/Pipeline/PRMT5 Inhibitor (Licensed to Bayer)

PRMT5 Inhibitor (Licensed to Bayer)

Not Specified

Phase 1Active (Licensed)

Key Facts

Indication
Not Specified
Phase
Phase 1
Status
Active (Licensed)
Company
Puhe Biopharma

About Puhe Biopharma

A China-based biotech developing AI-driven small-molecule drugs for cancer and immune disorders with a global-first-tier pipeline.

View full company profile

Therapeutic Areas

OncologyImmunologyMetabolic Diseases

Other Not Specified Drugs

DrugCompanyPhase
FL116Forlong BiotechnologyNot specified
FL117Forlong BiotechnologyNot specified
FL118Forlong BiotechnologyNot specified
FL301Forlong BiotechnologyNot specified
JSKN016AlphaMab OncologyPhase 1
JSKN033AlphaMab OncologyPhase 1
JSKN022AlphaMab OncologyPhase 1
JSKN027AlphaMab OncologyPhase 1
KN019AlphaMab OncologyPhase 1
New TCM FormulationsChina SXT PharmaceuticalsResearch / Pre-clinical
Long-acting LeronlimabCytoDynPreclinical
SR2162SIMR (Australia) BiotechIND Approved